This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Nissim Benvenisty | |
|---|---|
| Name | Nissim Benvenisty |
| Birth date | 1960s |
| Nationality | Israeli |
| Fields | Stem cell research, Genetics |
| Institutions | Hebrew University of Jerusalem, Hadassah Medical Center, Broad Institute |
| Alma mater | Hebrew University of Jerusalem |
| Known for | Pluripotent stem cell disease modeling, Human genetic engineering |
Nissim Benvenisty is an Israeli medical researcher and professor known for pioneering work in human pluripotent stem cell biology and genetic disease modeling. He leads a laboratory that integrates human embryonic stem cells, induced pluripotent stem cells, and genome editing technologies to study chromosomal disorders, cancer genetics, and neurodevelopmental disorders. His group is affiliated with institutions including the Hebrew University of Jerusalem, Hadassah Medical Center, and has collaborative links to centers such as the Broad Institute.
Born and raised in Israel, Benvenisty completed medical and graduate training at the Hebrew University of Jerusalem and clinical stints at Hadassah Medical Center. He undertook postgraduate research integrating clinical genetics and developmental biology, training alongside investigators from institutions like Harvard Medical School, Massachusetts Institute of Technology, and the Whitehead Institute. Early mentors and collaborators included scientists from Weizmann Institute of Science, Tel Aviv University, and international groups at the University of Cambridge and University of California, San Francisco.
Benvenisty established a research program focused on human pluripotent stem cell platforms, maintaining long-term ties with the Hebrew University of Jerusalem and collaborative networks at the Broad Institute and Weizmann Institute of Science. His laboratory employed techniques from groups at Stanford University, Columbia University, and Yale University to integrate CRISPR-Cas9 genome engineering, single-cell genomics developed at Broad Institute and Sanger Institute, and organoid methodologies pioneered at Hubrecht Institute and Hubert Humphrey. He has mentored trainees who moved to departments at Harvard University, MIT, Johns Hopkins University, and University College London.
Benvenisty’s group advanced protocols for deriving and characterizing human embryonic stem cell lines, building on foundational studies from Thomson Lab and Yamanaka Lab. They developed disease-in-a-dish models for Down syndrome, Prader–Willi syndrome, Angelman syndrome, and fragile X syndrome, integrating insights from research groups at Salk Institute and Cold Spring Harbor Laboratory. Using isogenic panels and genome editing, his team contributed to modeling glioblastoma and other oncology-related phenotypes in pluripotent contexts, collaborating conceptually with investigators from Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.
Key achievements include demonstrating chromosomal instability and aneuploidy dynamics in pluripotent cells, discoveries that intersect with literature from the Cancer Genome Atlas initiative and studies at Broad Institute. His lab pioneered methods for deriving haploid human embryonic stem cells and applied forward genetic screens using haploid platforms, drawing on approaches from Mouse Genetics programs at European Molecular Biology Laboratory and Wellcome Sanger Institute. Benvenisty’s application of CRISPR screens to human pluripotent cells complemented genome-wide efforts led by teams at Broad Institute and Stanford University. Collaborations extended to stem cell differentiation and organoid teams at Hubrecht Institute and Institute of Molecular Biotechnology (IMBA).
Benvenisty received national and international recognition, including prizes from Israeli scientific bodies linked to the Israel Academy of Sciences and Humanities and awards often shared among researchers associated with institutions such as Weizmann Institute of Science, Hebrew University of Jerusalem, and the Technion – Israel Institute of Technology. His work has been highlighted in conferences organized by the International Society for Stem Cell Research, European Molecular Biology Organization, and symposiums at Cold Spring Harbor Laboratory.
Benvenisty authored influential papers in high-profile journals alongside contributors from Broad Institute, Salk Institute, Harvard Medical School, and Weizmann Institute of Science. His publications on human pluripotent stem cell aneuploidy, haploid stem cell derivation, and disease modeling are frequently cited by groups at Stanford University, MIT, Yale University, and University of California, San Diego. The Benvenisty laboratory has shaped translational routes connecting basic pluripotent stem cell biology to clinical genetics programs at Hadassah Medical Center and collaborative translational centers like Sheba Medical Center. His trainees populate academic and biotechnology sectors including startups and research groups at Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Moderna, and biotech incubators in Cambridge, Massachusetts and Tel Aviv.
Category:Israeli scientists Category:Stem cell researchers